Article

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Liver international: official journal of the International Association for the Study of the Liver (Impact Factor: 4.41). 07/2011; 31 Suppl 2(2):30-60. DOI: 10.1111/j.1478-3231.2011.02539.x
Source: PubMed

ABSTRACT Decisions on public health issues are dependent on reliable epidemiological data. A comprehensive review of the literature was used to gather country-specific data on risk factors, prevalence, number of diagnosed individuals and genotype distribution of the hepatitis C virus (HCV) infection in selected European countries, Canada and Israel.
Data references were identified through indexed journals and non-indexed sources. In this work, 13,000 articles were reviewed and 860 were selected based on their relevance.
Differences in prevalence were explained by local and regional variances in transmission routes or different public health measures. The lowest HCV prevalence (≤ 0.5%) estimates were from northern European countries and the highest (≥ 3%) were from Romania and rural areas in Greece, Italy and Russia. The main risk for HCV transmission in countries with well-established HCV screening programmes and lower HCV prevalence was injection drug use, which was associated with younger age at the time of infection and a higher infection rate among males. In other regions, contaminated glass syringes and nosocomial infections continue to play an important role in new infections. Immigration from endemic countries was another factor impacting the total number of infections and the genotype distribution. Approximately 70% of cases in Israel, 37% in Germany and 33% in Switzerland were not born in the country. In summary, HCV epidemiology shows a high variability across Europe, Canada and Israel.
Despite the eradication of transmission by blood products, HCV infection continues to be one of the leading blood-borne infections in the region.

Download full-text

Full-text

Available from: Homie A Razavi, Jul 28, 2015
8 Followers
 · 
661 Views
  • Source
    • "We will discuss some of these shortcomings below. Even more patchy is the evidence concerning the disease burden , although recent studies have tried to fill the gap conducting intensive local surveys and expert interviews [12] [13] [14]. According to the study by Perz et al. [3], from the US Centers of Disease Control and Prevention, the attributable fractions of cirrhosis for HCV are 38% for Western and 34% for Eastern Europe [3], while those for hepatocellular carcinoma are, respectively, 44% and 15%. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The advent of potent and safe direct-acting antivirals against the hepatitis C virus has the potential of fulfilling the dream of eliminating this infection and its impact on global public health. However, even if effective drugs are at hand, most patients remain unaware of their infection, which may be recognized only in late stages when dire complications have occurred. Europe is not spared by this scourge, with its estimated 19,000,000 persons infected, and knowledge of the epidemiology of HCV and its drivers is a critical tool in fighting this virus. A thorough review is provided on the extent of the HCV epidemic across Europe, with a discussion of the most important subgroups affected, and of the risk factors of infection, both traditional and new.
    Digestive and Liver Disease 10/2014; DOI:10.1016/j.dld.2014.09.023 · 2.89 Impact Factor
  • Source
    • "In 2009, the overall HCV infection rate of 8.19 per 100,000 population was reported for 26 EU and EEA/EFTA Member States [20]. In 2011, Cornberg et al. [21] reviewed the prevalence of HCV in several countries and the lowest HCV prevalence estimates were from northern European countries, whilst the highest prevalence estimates were from Romania and rural areas in Greece and Italy, as well as portions of Russia. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) is endemic worldwide and according to the World Health Organization (WHO), there are about 150 million chronic carriers worldwide. The infection is a leading cause of liver diseases like cirrhosis and hepatocellular carcinoma (HCC); thus, HCV infection constitutes a critical public health problem. There are increasing efforts worldwide in order to reduce the global impact of hepatitis C through the implementation of programmatic actions that may increase the awareness of viral hepatitis and also improve surveillance, prevention, and treatment. In Brazil, about 1,5 million people have been chronically infected with HCV. The country has a vast territory with uneven population density, and hepatitis C incidence rates are variable with the majority of cases concentrated in the most populated areas. Currently, the main priorities of Brazilian Ministry of Health's strategies for viral hepatitis management include the prevention and early diagnosis of viral hepatitis infections; strengthening of the healthcare network and lines of treatment for sexually transmitted diseases, viral hepatitis, and AIDS; improvement and development of surveillance, information, and research; and promotion of universal access to medication. This review aims to summarize the available data on hepatitis C epidemiology and current status of efforts in prevention and infection control around the world and in Brazil.
    06/2014; 2014:827849. DOI:10.1155/2014/827849
  • Source
    • "Genotype 1 HCV is generally predominant throughout the world (Cornberg et al., 2011), but genotype 3 is also common in many regions. Genotype 3 accounts for more than 50% of HCV infections in India and Thailand, and approximately 30% in Australia and many European countries, including Great Britain, Germany, and Russia (Cornberg et al., 2011). Furthermore , genotype 3 HCV infection is associated with higher incidence of liver steatosis and hepatocellular carcinoma (Nkontchou et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Infection with genotype 3 hepatitis C virus (HCV) is common throughout the world, however no direct-acting antiviral (DAA) has been approved to treat this genotype. We therefore attempted to develop novel genotype 3 replicons to facilitate the discovery and development of new HCV therapies. A novel Huh-7-derived cell line 1C but not Lunet cells enabled the selection of a few stable colonies of a genotype 3a subgenomic replicon (strain S52). Genotypic analysis revealed a mutation of P89L in the viral NS3 protease domain, which was confirmed to enhance genotype 3a RNA replication and enable the establishment of highly replicating luciferase-encoding replicons. Secondary adaptive mutations that further enhanced RNA replication were identified in the viral NS3 and NS4A proteins. In addition, cell lines that were cured of genotype 3a replicons demonstrated higher permissiveness specifically to genotype 3a HCV replication. These novel replicons and cell lines were then used to study the activity of approved and experimental HCV inhibitors. NS3 protease and non-nucleoside NS5B polymerase inhibitors often demonstrated substantially less antiviral activity against genotype 3a compared to genotype 1b. In contrast, nucleoside analog NS5B inhibitors and host-targeting HCV inhibitors showed comparable antiviral activity between genotypes 3a and 1b. Overall, the establishment of this novel genotype 3a replicon system, in conjunction with those derived from other genotypes, will aid the development of treatment regimens for all genotypes of HCV.
    Antiviral research 09/2013; 100(2). DOI:10.1016/j.antiviral.2013.08.018 · 3.94 Impact Factor
Show more